Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
May, 2026
May 2026
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early
Umar Jawed/LinkedIn
Apr 12, 2026, 21:52

Umar Jawed: The Most Dangerous Anti-D Result Is Not the Highest One – It’s the One You Underestimate Early

Umar Jawed, Consultant Haematologist at King’s College Hospital London, Jeddah, shared a post on LinkedIn:

“‘The most dangerous Anti-D result is not the highest one – it’s the one you underestimate early.’

My morning today at King’s College Hospital London – Jeddah started with exactly that.

A routine antenatal screen.

Young patient. Early gestation.

  • Anti-D detected.
  • Titre: High.

And instantly, what looks like a lab result becomes a time-sensitive fetal risk assessment problem.

Because:

  • High-titre Anti-D this early is never reassuring.

It raises one critical question:

Are we already behind in this pregnancy?

The Clinical Shift (Not Just ‘Follow the Titre’)

Following principles from Royal College of Obstetricians and Gynaecologists (RCOG), British Committee for Standards in Haematology (BCSH) and American College of Obstetricians and Gynecologists (ACOG):

This was not a ‘watch and wait’ case.

Management mindset shifted immediately to:

  • Early risk stratification
  • Urgent fetal medicine referral
  • Consideration of fetal RhD genotyping (non-invasive where available)
  • Planning for MCA Doppler surveillance

Because once sensitisation is established:

Titre is not the disease – fetal anemia is.

What Makes Anti-D Different

In transfusion medicine, Anti-D is unique:

  • Preventable – yet still encountered
  • Predictable – yet still underestimated
  • Detectable early – but often acted on late

And importantly:

Early high titre is not equal mild disease starting early

It may reflect a sensitised immune system already primed for rapid fetal impact

The Bigger Perspective

This is where transfusion medicine extends beyond the lab.

It becomes:

  • Predictive medicine
  • Fetal risk stratification
  • Multidisciplinary decision-making

Because one antibody, detected at the right time, can completely alter the trajectory of a pregnancy.

Questions for colleagues in transfusion and fetal medicine:

  • At what titre (and gestation) do you escalate immediately to fetal medicine?
  • Are you routinely integrating non-invasive fetal RhD typing into your pathway?”

Umar Jawed

Stay updated on Hemostasis Today.

ACOG American College of Obstetricians and Gynecologists BCSH British Committee for Standards in Haematology Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine RCOG Royal College of Obstetricians and Gynaecologists Umar Jawed
NewsFeed